Nanotein & Akron Bio Partner for cGMP production of NanoSpark® STEM-T Soluble T Cell Activator. Read More

Call Us: +1 (866) 82T CELL (2355)

Call Us

About Us

Nanotein Technologies Segmented Hexagon Logo 1

In 2019, Curtis Hodge and Greg Hura established Nanotein building off of a technology they developed at Lawrence Berkeley National Lab. To achieve this they leveraged their expertise in protein engineering and cancer immunology. 

T Cell Therapy and CAR-T Overview

  • T cells are one of the body's most powerful defense mechanisms. Under normal conditions T cells identify and destroy both pathogens and abnormal/cancerous cells.
  • Cancer can disrupt the natural abilities of T cells by shutting down their targeting and activation systems. Chimeric antigen receptors (CAR)s are engineered molecules that restore and enhance T cells' potent, cancer-fighting properties.
  • Manufacturing T cells for therapeutic use is a technologically and logistically complex process that Nanotein aims to help improve.

Leadership

Our experienced leadership team is trailblazing a path to market by combining innovation and entrepreneurship to bring transformative technologies to the world of healthcare.

Curtis Hodge CEO Nanotein Technologies Headshot

Curtis Hodge, PhD

Co-Founder & CEO

Greg Hura CSO Nanotein Technologies Headshot

Greg Hura, PhD

Co-Founder & CSO

Our Strategic Partner

Nanotein partnered with Polaris Group, a developer of novel cancer treatments, in 2020. Polaris is a major investor and manufacturing partner of Nanotein.

Polaris Group Strategic Partner Logo

Are you a T cell therapy or academic T cell researcher?

Nanotein is interested in collaborations.

Get In Touch
Nanotein Technologies White Logo

2950 San Pablo Ave
Berkeley, CA 94702
info@nanoteintech.com
+1 866 828-2355

Linkedin

Subscribe to Our Newsletter

© 2025 Nanotein Technologies. All Rights Reserved.
4 shaded squares

Biotech website design